In continuing to develop new and improved OVs, researchers have been vigilant in optimizing their ability to selectively infect and replicate within tumors and induce an immune response while striving to minimize toxicity. One key limitation is that modifications of viruses often negatively impact their ability to infect, propagate, and spread within the tumor. Furthermore, induction of strong immune responses also promotes rapid viral clearance. We investigate wild-type HRVs as a novel class of OV. Multiple HRV serotypes were propagated in human melanoma cell lines to produce highly oncolytic populations of virus. We infected a large panel of cancer types and evaluated cytotoxicity using flow cytometry and real time live imaging. Pro-inflammatory signaling was assessed by cytokine multiplexing. Tumor responses to HRV were assessed in human xenograft and in syngeneic, immune-competent mouse tumor models. We find that HRVs are capable of infecting and killing a wide variety of human cancer cell lines in vitro and in vivo induce pro-inflammatory responses and tumor regression. We propose that the natural safety profile of these viruses, coupled with their anti-tumor efficacy and multivalent potential seen in our preclinical model systems, make HRVs ideal candidates for development as oncolytic viruses for clinical testing.